# Advanced procedures now have the closure they deserve.

Maintain wire access until hemostasis is confirmed.

Repositionable and recoverable.*

Bioabsorbable and sutureless.

No preclose or preprocedural steps.

**0%** MAJOR | **1.9%** MINOR

Complications per VARC-3.[1]

## PerQseal® Elite Vascular Closure System



### Technical Specifications

| | |
|---|---|
| Arterial Closure Range | 14-22F ID sheath (arteriotomy up to 26F OD) |
| Introducer Size | 18F OD, 7.3 mm (18F ID, Effective length 15 cm) |
| Guidewire Compatibility | 0.035" (0.89 mm) — Minimum length 150 cm |
| Anchoring System | Active external fixation |
| Bioabsorption | Full bioabsorption expected within ~180 days |
| Pre-procedural Steps Required | None |
| Wire Access Until Release | Yes |
| Patch Thickness | 230 µm |
| Devices per Arteriotomy | 1 PerQseal device |

**Scan to learn more about PerQseal Elite**

### Ordering Information

| Product | Catalog Number | Contents |
|---|---|---|
| PerQseal Elite Large-Bore Closure System | DP4-P1-2-E | PerQseal Elite Closure Device + PerQseal Elite Introducer Sheath |

Please consult product labels, and instructions for use for indications, contraindications, warnings, precautions and adverse events. See PerQseal Elite IFU DP4-C56-5.

For a list of worldwide office locations and contact information, visit www.haemonetics.com/officelocations

* Repositionable and recoverable prior to implant release

1. Results from the prospective, single-arm, multi-center ELITE arterial study; VARC-3 major and minor device-related vascular access site complications (adjudicated) through 30 days. Per protocol (PP) population, N=106. See PerQseal® Elite instructions for use.

**www.haemonetics.com/IVT**
800-537-2802

© 2026 Haemonetics Corporation. Haemonetics and PerQseal are trademarks or registered trademarks of Haemonetics Corporation in the U.S., other countries or both. 10.2026 USA. COL-COPY-002889-US(AA)

HAEMONETICS®

# PerQseal® Elite
Vascular Closure System

# Close with confidence.

Achieve near-instant hemostasis with one device. No preprocedural steps. No major complications per VARC-3.[1] And nothing permanent left behind.



HAEMONETICS®

# Purpose-built for **large-bore closure.**

Large-bore vascular closure solutions haven't kept up with technological breakthroughs and procedural advancements. Until now.

## Don't complicate it.

**One device and done.**
Over-the-wire delivery with no preclose or preprocedural steps. Deploy at the end of the primary procedure. Leave nothing permanent behind.

**0% major complications per VARC-3.**[1]

## Confirm before you commit.

**Repositionable and recoverable.***
Maintain wire access until hemostasis is verified, prior to implant release.


**Near-instant hemostasis.**
Mean time to achieve hemostasis is < 1 minute.[1]

## Respect the vessel.


**Patch, don't pinch.**
Close with no sutures, no purse-string effect.

**100% bioabsorbable.**
Leave nothing permanent behind. Vessel expected to return to its natural state within ~180 days.




Deliver the device over the wire — without any preprocedural steps. Maintain 0.035" guidewire access as you position the patch.




Confirm hemostasis before you deploy the device. No sutures necessary. Full implant bioabsorption expected within ~180 days.




Patch encapsulated.




Implant bioabsorption in progress.




Full bioabsorption expected, vessel restored.